Annual General Meeting held in OssDsign AB
11 juni, 14:00
Annual General Meeting held in OssDsign AB
11 June 2025. Today, the annual general meeting of 2025 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting (complete information and documents regarding the decisions of the meeting are available on the company’s website www.ossdsign.com).
The annual general meeting resolved:
-to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2024;
-that the company’s result shall be carried forward in new account and that no dividend shall be paid;
-to grant the board members and the CEO discharge from liability for the financial year 2024;
-that the board of directors shall consist of five ordinary members without deputy members, to re-elect Simon Cartmell, Christer Fåhraeus, and Jill Schiaparelli as ordinary board members, election of David Jern and Tomas Blomquist as new ordinary board members, and to re-elect Simon Cartmell as chairman of the board;
-that a registered accounting firm shall be elected as auditor and to re-elect Ernst & Young AB as the company’s auditor;
-that fees payable to the board members until the end of the next annual general meeting shall amount to a total of SEK 1,300,000 out of which SEK 400,000 shall be paid to the chairman and SEK 300,000 to each of the other board members except for Christer Fåhraeus to whom no board fee is to be paid;
-that the auditor is to be paid in accordance with approved invoices;
-on an authorization for the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures through which the company’s share capital may be increased by an amount corresponding to not more than twelve (12) per cent of the share capital after such issue(s);
-to adopt the board's proposed resolution on a long-term incentive program for employees and contractors through a directed issue of no more than 480,000 warrants to the company and/or any of its subsidiaries and approval of the subsequent transfer of the issued warrants to certain employees and contractorswithin the group against payment of the market value of the option right or, provided that it does not entail negative tax consequences for the group, free-of-charge. Each warrant entitles the holder to subscribe for one (1) new share in the company, as adjusted downwards by application of the mandatory so-called quotient exercise model set forth in the proposed resolution, during the period from and including 1 July 2028 until and including 31 December 2028, against payment of a subscription price per new share corresponding to 140 percent of the volume weighted average trading price for the company’s share on Nasdaq First North Growth Market during a period of ten trading days before the annual general meeting. The warrants are governed by customary terms and conditions, including any adjustments to the subscription price and the number of new shares that each warrant entitles the holder to subscribe for in the event of certain events affecting the company; and
-to not adopt the resolution proposed by certain shareholders regardinga long-term incentive programme for board members including a directed issue of warrants and approval of transfer of warrants.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Mob: +46 73 382 43 90
morten.henneveld@ossdsign.com
Certified Adviser:
The company’s Certified Adviser is DNB Carnegie Investment Bank AB.
Publication
This information was submitted for publication, through the agency of the contact persons set out above, on 11 June 2025, 14.00 CEST.
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Ämnen i artikeln
Annual General Meeting held in OssDsign AB
11 juni, 14:00
Annual General Meeting held in OssDsign AB
11 June 2025. Today, the annual general meeting of 2025 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting (complete information and documents regarding the decisions of the meeting are available on the company’s website www.ossdsign.com).
The annual general meeting resolved:
-to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2024;
-that the company’s result shall be carried forward in new account and that no dividend shall be paid;
-to grant the board members and the CEO discharge from liability for the financial year 2024;
-that the board of directors shall consist of five ordinary members without deputy members, to re-elect Simon Cartmell, Christer Fåhraeus, and Jill Schiaparelli as ordinary board members, election of David Jern and Tomas Blomquist as new ordinary board members, and to re-elect Simon Cartmell as chairman of the board;
-that a registered accounting firm shall be elected as auditor and to re-elect Ernst & Young AB as the company’s auditor;
-that fees payable to the board members until the end of the next annual general meeting shall amount to a total of SEK 1,300,000 out of which SEK 400,000 shall be paid to the chairman and SEK 300,000 to each of the other board members except for Christer Fåhraeus to whom no board fee is to be paid;
-that the auditor is to be paid in accordance with approved invoices;
-on an authorization for the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures through which the company’s share capital may be increased by an amount corresponding to not more than twelve (12) per cent of the share capital after such issue(s);
-to adopt the board's proposed resolution on a long-term incentive program for employees and contractors through a directed issue of no more than 480,000 warrants to the company and/or any of its subsidiaries and approval of the subsequent transfer of the issued warrants to certain employees and contractorswithin the group against payment of the market value of the option right or, provided that it does not entail negative tax consequences for the group, free-of-charge. Each warrant entitles the holder to subscribe for one (1) new share in the company, as adjusted downwards by application of the mandatory so-called quotient exercise model set forth in the proposed resolution, during the period from and including 1 July 2028 until and including 31 December 2028, against payment of a subscription price per new share corresponding to 140 percent of the volume weighted average trading price for the company’s share on Nasdaq First North Growth Market during a period of ten trading days before the annual general meeting. The warrants are governed by customary terms and conditions, including any adjustments to the subscription price and the number of new shares that each warrant entitles the holder to subscribe for in the event of certain events affecting the company; and
-to not adopt the resolution proposed by certain shareholders regardinga long-term incentive programme for board members including a directed issue of warrants and approval of transfer of warrants.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Mob: +46 73 382 43 90
morten.henneveld@ossdsign.com
Certified Adviser:
The company’s Certified Adviser is DNB Carnegie Investment Bank AB.
Publication
This information was submitted for publication, through the agency of the contact persons set out above, on 11 June 2025, 14.00 CEST.
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Ämnen i artikeln
-992x558.jpg&w=3840&q=75)
Veckans analyser
.jpg&w=3840&q=75)
-992x558.png&w=3840&q=75)
-992x558.jpg&w=3840&q=75)
Fortnox-budet
-992x558.png&w=3840&q=75)
Veckans analyser
Fortnox-budet
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
-160x160.png&w=3840&q=75)
